Tüdőrák: vizsgálatok itt: Hollandia
141 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Amersfoort, Breda, Groningen, Leiden, Nieuwegein, Rotterdam, Zwolle
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - 3. fázisFut, nem toborozA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Amsterdam, Arnhem, Groningen
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - 2. fázisTaking peopleKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Where
- Deventer, Leiden
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00 - 3. fázisTaking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Amsterdam, Maastricht, Rotterdam
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - 1/2. fázisNot yet taking people in HollandiaA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- Where
- Groningen
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00 - 3. fázisTaking peopleA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Arnhem, Heerlen, Leiden
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - 3. fázisNot yet taking people in HollandiaA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Geleen, 'S-Hertogenbosch
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Amsterdam, Groningen
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 3. fázisFut, nem toborozStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Amsterdam, Groningen, Maastricht, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00 - 1/2. fázisTaking peopleA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Amsterdam, Nijmegen
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Amersfoort, Amsterdam, Arnhem, Breda, Harderwijk, Leidschendam, Zwolle
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Amsterdam, Maastricht, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - 3. fázisTaking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Amsterdam, Breda, Groningen, Nijmegen, Zwolle
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - 1. fázisNot yet taking people in HollandiaPhase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655 - 3. fázisTaking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Enschede, Harderwijk, Hilversum, Leeuwarden, Leiden, Rotterdam, 's-Hertogenbosch, Tilburg, Utrecht
- Életkor
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - 3. fázisFut, nem toborozA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - 3. fázisTaking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Amsterdam, Breda, Harderwijk, Maastricht, Tilburg, Utrecht, Zwolle
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - 3. fázisBefejeződöttA Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
- Where
- Maastricht
- Életkor
- 18 év and over
- People
- 65 worldwide
- Run by
- Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Breda, Tilburg, Zwolle
- Életkor
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - 2. fázisTaking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Where
- Amsterdam, Nijmegen
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00 - 2. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Amsterdam, Dordrecht, Harderwijk, Nijmegen, Schiedam, 's-Gravenhage
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1/2. fázisTaking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Harderwijk, Maastricht, 's-Gravenhage, 'S-Hertogenbosch, Zwolle
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00